CATEGORY
NICE
- ABPI
- ACE
- ACIS
- Adelaide
- Aetsa
- Agenas
- AHRQ
- AIFA
- AMNOG
- ANVISA
- AOTMiT
- AQuAS
- Behandlingsraadet
- BfArM
- Biocat
- C2H
- CADTH
- CDC
- CDE
- CMS
- COFEPRIS
- CONITEC
- Digemid
- EFPIA
- EMA
- EPF
- Eucope
- EUnetHTA
- EuropaBio
- European Commission
- Euskadi
- FDA
- FOPH
- G-BA
- Gesundheit Österreich
- HAS
- Health Technology Wales
- Healthcare Improvement Scotland
- HHS
- HIQA
- HTAi
- ICER
- IECS
- IETS
- IHE
- IHEA
- INAHTA
- IQWiG
- ISPOR
- KCE
- Medicaid
- Medicines for Europe
- MHRA
- MSP
- NECA
- NHS
- nHTA
- NICE
- NIH
- NIHO
- NIHR
- NIPH
- NSW Health
- NZa
- OHE
- OYS
- PBS
- pCPA
- Pharmac
- PhRMA
- Salute
- SBU
- Schönermark Kielhorn Collegen
- SGK
- TÄ°TCK
- TLV
- WHO
- ZonMw
- Zorginstituut Nederland
NICE Endorses Affordable Ublituximab for Relapsing Multiple Sclerosis Patients
Ultrasound Subthalamotomy Requires More Research, Says NICE
NICE’s Severity Modifier Leads to More Treatment Approvals
NICE Sticks to Established Cost-Effectiveness Limits as Drug Prices Rise
NICE Approves Elranatamab for Specific Multiple Myeloma Patients
NICE Delays Approval of Loqtorzi Combination Therapy for Advanced Oesophageal Cancer
NICE Approves Affordable Vamorolone for Duchenne Muscular Dystrophy
NICE Launches Targeted Rollout of Tirzepatide for Severe Obesity
NICE Endorses Cost-Effective Bevacizumab Gamma for Wet AMD Treatment
NICE Endorses Crizotinib for Targeted Lung Cancer Treatment
NICE Strengthens Public Role in Healthcare Research
NICE Approves AstraZeneca’s Eplontersen for Hereditary Amyloidosis Treatment
New Joint Guidelines Set to Elevate Asthma Care Across the UK
NICE Endorses Digital Treatments for Tourette’s and Chronic Tic Disorders
NICE Launches Sandbox Approach to Modernize Health Technology Assessments